Market Cap 384.94M
Revenue (ttm) 57.56M
Net Income (ttm) -44.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -76.69%
Debt to Equity Ratio -0.44
Volume 2,314,527
Avg Vol 1,325,166
Day's Range N/A - N/A
Shares Out 99.72M
Stochastic %K 21%
Beta 1.99
Analysts Strong Sell
Price Target $8.42

Company Profile

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 908 941 1900
Address:
30 Technology Drive, Warren, United States
Outrageous
Outrageous Aug. 27 at 8:24 PM
$AQST This is very intersesting! I asked AI this question: The epipen patton expires on September 11th, 2025. Would VIATRIS be interested in purchasing another company that has a device free sublingual film to treat anaphylaxis? AI's Answer: It is highly probable that Viatris would be interested in acquiring a company developing a device-free sublingual film for anaphylaxis. With the EpiPen patent expiring in September 2025, Viatris is losing its market exclusivity and facing significant competition from generic auto-injectors. A novel product like a sublingual film could help them regain a competitive edge in the epinephrine delivery market.
0 · Reply
h8ster
h8ster Aug. 27 at 8:22 PM
$AQST Look at the patterns. If we had this market valuation range, which has fluctuated from $470M - $495M...... without the offering, that would give us a pps between $4.72 - $4.95. We don't get to see those prices due to being diluted the F out of. All times we traded that range, pre offering, price action has been very volatile and faced big resistance. 80% or more of the volume here is all algorithmic. Right now, we have post offering volatility which is always high. Its going to stay that way for a multitude of reasons until we hit those September conferences and get additional clarity on things such as possible Ex-US partnership, 108 trials coming off the shelf, AdCom stuff, etc. A big dip is very possible. Have money ready to load up on the mistakes of others, should the market gift us of a large dip.
0 · Reply
Bchaps
Bchaps Aug. 27 at 8:06 PM
$AQST mmm 7% dumpy day from high to close. Interested to see how this closes the week. This sideways chop seems like it’s trying to digest not only the 60ish% move off the lows plus the new shares. Honestly, If it remains around here (+/- $.20-$.30) think it’s a big win.
1 · Reply
Dcastle
Dcastle Aug. 27 at 8:03 PM
$AQST Triple bottom on the weekly......tomorrow will tell the story
0 · Reply
essiepaul
essiepaul Aug. 27 at 8:02 PM
$AQST what a surprise.
0 · Reply
BigGainTom
BigGainTom Aug. 27 at 8:00 PM
$AQST Sorry but this is one of the shittiest stocks I have ever held. I hope I can sell at $10.
2 · Reply
h8ster
h8ster Aug. 27 at 7:55 PM
$AQST Gimme my 10K shares in $3.50's.
1 · Reply
BigGainTom
BigGainTom Aug. 27 at 7:51 PM
$AQST Come on, this is bullshit
0 · Reply
h8ster
h8ster Aug. 27 at 7:43 PM
$AQST I'm assuming everybody that has been here since 2024 or earlier knows that an AdCom is already factored into the pps. When the FDA notes were released late last year, which showed the FDA concerns on the Anaphylm studies, and when the FDA itself, literally said the following, (below), an AdCom started to become factored in. "Due to the new route of administration and the data supporting this route of administration, an advisory committee meeting may be necessary.” After this release, AQST's downtrend rapidly accelerated thing us from the $5's down to the $2's. Then, management started its intense and expensive prep for a possible AdCom, as they have talked about in every conference call, etc, since. The company expects one. The market expects one. The only ones that don't are retail traders. Take advantage of their mistake. Should we need an AdCom and the price falls, be ready to load up. Have cash ready. Be smart. If one isn't needed, enjoy the surge upwards!
2 · Reply
BigGainTom
BigGainTom Aug. 27 at 6:40 PM
$AQST "no AdCom" would be perceived as good news. That would imply that the FDA is satisfied with the submitted data and sees no points for further discussions.
1 · Reply
Latest News on AQST
Aquestive Therapeutics: Five Foci For 2025

Jan 6, 2025, 12:13 AM EST - 8 months ago

Aquestive Therapeutics: Five Foci For 2025


Aquestive: Rare Opportunity With Dual Platform Strategy

Nov 5, 2024, 2:09 PM EST - 10 months ago

Aquestive: Rare Opportunity With Dual Platform Strategy


Aquestive Therapeutics: Bullish Roadmap After Q2 Earnings

Aug 22, 2024, 11:37 PM EDT - 1 year ago

Aquestive Therapeutics: Bullish Roadmap After Q2 Earnings


Outrageous
Outrageous Aug. 27 at 8:24 PM
$AQST This is very intersesting! I asked AI this question: The epipen patton expires on September 11th, 2025. Would VIATRIS be interested in purchasing another company that has a device free sublingual film to treat anaphylaxis? AI's Answer: It is highly probable that Viatris would be interested in acquiring a company developing a device-free sublingual film for anaphylaxis. With the EpiPen patent expiring in September 2025, Viatris is losing its market exclusivity and facing significant competition from generic auto-injectors. A novel product like a sublingual film could help them regain a competitive edge in the epinephrine delivery market.
0 · Reply
h8ster
h8ster Aug. 27 at 8:22 PM
$AQST Look at the patterns. If we had this market valuation range, which has fluctuated from $470M - $495M...... without the offering, that would give us a pps between $4.72 - $4.95. We don't get to see those prices due to being diluted the F out of. All times we traded that range, pre offering, price action has been very volatile and faced big resistance. 80% or more of the volume here is all algorithmic. Right now, we have post offering volatility which is always high. Its going to stay that way for a multitude of reasons until we hit those September conferences and get additional clarity on things such as possible Ex-US partnership, 108 trials coming off the shelf, AdCom stuff, etc. A big dip is very possible. Have money ready to load up on the mistakes of others, should the market gift us of a large dip.
0 · Reply
Bchaps
Bchaps Aug. 27 at 8:06 PM
$AQST mmm 7% dumpy day from high to close. Interested to see how this closes the week. This sideways chop seems like it’s trying to digest not only the 60ish% move off the lows plus the new shares. Honestly, If it remains around here (+/- $.20-$.30) think it’s a big win.
1 · Reply
Dcastle
Dcastle Aug. 27 at 8:03 PM
$AQST Triple bottom on the weekly......tomorrow will tell the story
0 · Reply
essiepaul
essiepaul Aug. 27 at 8:02 PM
$AQST what a surprise.
0 · Reply
BigGainTom
BigGainTom Aug. 27 at 8:00 PM
$AQST Sorry but this is one of the shittiest stocks I have ever held. I hope I can sell at $10.
2 · Reply
h8ster
h8ster Aug. 27 at 7:55 PM
$AQST Gimme my 10K shares in $3.50's.
1 · Reply
BigGainTom
BigGainTom Aug. 27 at 7:51 PM
$AQST Come on, this is bullshit
0 · Reply
h8ster
h8ster Aug. 27 at 7:43 PM
$AQST I'm assuming everybody that has been here since 2024 or earlier knows that an AdCom is already factored into the pps. When the FDA notes were released late last year, which showed the FDA concerns on the Anaphylm studies, and when the FDA itself, literally said the following, (below), an AdCom started to become factored in. "Due to the new route of administration and the data supporting this route of administration, an advisory committee meeting may be necessary.” After this release, AQST's downtrend rapidly accelerated thing us from the $5's down to the $2's. Then, management started its intense and expensive prep for a possible AdCom, as they have talked about in every conference call, etc, since. The company expects one. The market expects one. The only ones that don't are retail traders. Take advantage of their mistake. Should we need an AdCom and the price falls, be ready to load up. Have cash ready. Be smart. If one isn't needed, enjoy the surge upwards!
2 · Reply
BigGainTom
BigGainTom Aug. 27 at 6:40 PM
$AQST "no AdCom" would be perceived as good news. That would imply that the FDA is satisfied with the submitted data and sees no points for further discussions.
1 · Reply
h8ster
h8ster Aug. 27 at 6:36 PM
$AQST Price action is so far going as expected. Love seeing it just because it's so textbook. Would love it even more if it held gains, which would mean the required post offering process has been completed with the underwriters, and profit taking has ended, with the market valuation still being up so high after the offering closed. Like I said before, as retail investors, we can't have our cake and eat it to. While it's great to see AQST's market valuation shoot up close to half a billion, the heavy dilution makes it so we don't see the ROI. It's the Ying/Yang for these types of positive events. Tute investors and algo's are locking in profits with that high of a valuation thinking "how much higher can it go short term given general market concerns and risks". They are playing it safe. The real test will be once the underwriters have liquidated their pps stabilization positions and we return to normal buying/selling activity.
0 · Reply
BigGainTom
BigGainTom Aug. 27 at 6:21 PM
$AQST stock price retracted 23 cents today only. Insane
1 · Reply
Falcones
Falcones Aug. 27 at 5:52 PM
$AQST Volume exceeds price again. Looks like institutions accumulating without moving the price too much.
2 · Reply
BackAgainAfterCensorship
BackAgainAfterCensorship Aug. 27 at 5:16 PM
$AQST so buy more at 3.86 😂 this also is 😴
0 · Reply
ClearCities
ClearCities Aug. 27 at 5:14 PM
$AQST all we need now is for trump, elon, pelosi, and the rest of ancient dinosaurs to all get anaphylaxis and go inti a shock to use anaphylm. This should go 1,000 dollars per share
0 · Reply
BigGainTom
BigGainTom Aug. 27 at 5:11 PM
$AQST just like I predicted earlier today. Brief spike to 4 in the mid day and then close red.
1 · Reply
Sofi2024
Sofi2024 Aug. 27 at 4:59 PM
$AQST that was a good chunk
0 · Reply
Bchaps
Bchaps Aug. 27 at 4:43 PM
$AQST the allergy to $4 is severe enough that it may need to take some anaphylm
1 · Reply
BigGainTom
BigGainTom Aug. 27 at 4:40 PM
$AQST Do not listen to career day traders for medical knowledge. Bad idea. Anaphylaxis is most commonly a mild reaction, like hives. These reactions do not require any therapy or maybe Benadryl at most. Severe reactions like shortness of breath or worse require Epi. These are the extreme minority of reactions, like less than 5%. I deal with this every day at my job. To say that seizures is less of an emergency than anaphylaxis is a very stupid statement. During seizures, people fall down and suffer trauma and aspirate gastric contents. These can be life threatening! My point is that if a rescue drug like Libervant did not need an AdCom, how can you say Anaphylm will require one? Very naive.
0 · Reply
BigGainTom
BigGainTom Aug. 27 at 4:23 PM
$AQST Great company but stock sucks. I think it will make one last shoot up to 4 today and then close red.
0 · Reply
richb477
richb477 Aug. 27 at 4:15 PM
$AQST Green would be nice again today but looking like another shit burger. Its going to be a roller coaster for awhile. May need rehab by the time this pays off🤪
0 · Reply
michener99
michener99 Aug. 27 at 3:52 PM
$AQST One of these days Alice , POW right in the kisser!
0 · Reply